1. Academic Validation
  2. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3

N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3

  • Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301. doi: 10.1016/j.bmcl.2006.12.003.
Richard M Angell 1 Francis L Atkinson Murray J Brown Tsu Tshen Chuang John A Christopher Maria Cichy-Knight Allison K Dunn Kendra E Hightower Susanna Malkakorpi James R Musgrave Margarete Neu Paul Rowland Robyn L Shea Jeffery L Smith Donald O Somers Sonia A Thomas Gladstone Thompson Ruolan Wang
Affiliations

Affiliation

  • 1 GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.
Abstract

The identification and exploration of a novel, potent and selective series of N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amide inhibitors of JNK2 and JNK3 kinases is described. Compounds 5a and 11a were identified as potent inhibitors of JNK3 (pIC50 6.7 and 6.6, respectively), with essentially equal potency against JNK2 (pIC50 6.5). Selectivity within the mitogen-activated protein kinase (MAPK) family, against JNK1, p38alpha and ERK2, was observed for the series. X-ray crystallography of 5e and 8a in JNK3 revealed a unique binding mode, with the 3-cyano substituent forming an H-bond acceptor interaction with the hinge region of the ATP-binding site.

Figures
Products